Sales of three major pharmaceutical cannabis products are expected to reach 1.8 billion euros by 2025


The Pharmaceutical Cannabis Report: 2nd Edition published today by Prohibition Partners states that research into the endocannabinoid system is currently one of the most promising – and potentially lucrative – avenues for new therapeutics in medicine.

The report highlights how the use of cannabinoids in the treatment of conditions ranging from pain and spasticity to PTSD and epileptic seizures offers great opportunities, with current global spending on non-cannabinoid-based pain relievers at US $ 63-85 billion worldwide – Dollars are valued every year.

To date, not a single cannabinoid-based drug has received broad approval for the treatment of pain, although this is by far the most common condition for which medicinal cannabis is used.

The market for pharmaceutical products that use the endocannabinoid system to treat diseases is still largely untapped. With 200 million people using cannabis worldwide each year, coupled with findings from Prohibition Partners’ worldwide surveys of cannabis users in 2020, studies show that around 40% of cannabis users have a medicinal component in their use.

Understanding what cannabinoids can be used for in the medical setting has previously been largely guided by patients, with research often following for a specific condition in lieu of general cannabis use.

Despite the ubiquity of the endocannabinoid system (ECS) in the human body and the system’s apparent involvement in most human diseases, there are only a handful of drugs on the market that modulate the ECS.

Epidolex® is currently the leading cannabinoid drug with sales of over 430 million euros in 2020 and serves an estimated population of more than 20,000. It took the drug maker GW Pharmaceuticals over 20 years to generate significant sales and suffered many setbacks in clinical trials. In the meantime, however, sales are growing rapidly, so that the company has now been taken over by Jazz Pharmaceuticals with a value of over 5 billion euros.

Prohibition Partners’ The Pharmaceutical Cannabis Report: 2nd Edition identifies at least 30 late-stage clinical trials of cannabinoid therapeutics, each of which could have a major impact on the medical cannabis space. Products with new routes of administration are going through the approval process, while research and development on smaller cannabinoids with great therapeutic potential is only just beginning.

It is believed that around 250 clinical trials of agents targeting the ECS are conducted each year. Given the central metabolic role that the ECS plays, there is plenty of room for growth in these numbers.

The potential for the use of medical cannabinoids in the pharmaceutical sector has hardly been exhausted. In the medium to long term, the report suggests that a number of new cannabinoid therapeutics will be approved worldwide. Operators in this area can expect these products to gain market share over the next ten years at the expense of unapproved flowers and oils.

Barbara Pastori, director of strategy and data at Prohibition Partners, said, “The goal of getting established in medical cannabis is a very moving goal. The balance between approved and unapproved products is constantly shifting, and new innovations in the highly medicated cannabis sector promise to turn the current status quo in the industry a little on its head. Therefore, Prohibition Partners is offering this report along with our advisory services to anyone who wants to know where they belong in this rapidly evolving industry. We offer industry-leading insights and strategic advice for anyone looking to establish or expand their position in the value chain. ”

Conor O’Brien, author of the report and analyst at Prohibition Partners, said: “Many operators in the medical cannabis arena are blind to the risks and rewards of the latest developments in clinical trials of cannabinoid drugs, the synthetic cannabinoid Space and innovations in delivery formats and devices. This report describes the current state of medical cannabis technologies and treatments that will inevitably occupy a large portion of the medical cannabis market in the future, with implications for all patients, regulators and operators in this area. “

The Pharmaceutical Cannabis Report: 2nd Edition delves into the use of cannabinoids in the treatment of disease and how this presents both challenges and opportunities for anyone working in space. The report paints a clearer picture for the future of the pharmaceutical cannabis sector.

For more information, the executive summary of The Pharmaceutical Cannabis Report: 2nd Edition can be downloaded here. For press inquiries, please contact Michael Hoban (

About prohibition partners

Prohibition Partners unlocks the potential of cannabis through data, intelligence and strategy. We provide strategic solutions and advisory services to an international client base of investors, operators, blue chip companies, FMCG brands and government agencies.